The oncogenic transcription factor AP-1 (activator protein-1) is required for tumor promotion and progression. Identification of novel and specific AP-1 inhibitors would be beneficial for cancer prevention and therapy. The authors have developed a high-throughput assay to screen synthetic and natural product libraries for noncytotoxic inhibitors of mitogen-activated AP-1 activity. The cell-based high-throughput screen is conducted in a 384-well format using a fluorescent resonance energy transfer (FRET) substrate to quantify the activity of a β-lactamase reporter under the control of an AP-1-dependent promoter. The ratiometric FRET readout makes this assay extremely robust and reproducible, particularly for use with natural product extracts. To eliminate false positives due to cell killing, a cytotoxicity assay was incorporated. The AP-1 β-lactamase reporter was validated with inhibitors of kinases located upstream of AP-1 and with known natural product inhibitors of AP-1 (nordihydroguaiaretic acid and curcumin). The assay was able to identify other known AP-1 inhibitors and protein kinase C modulators, as well as a number of chemically diverse compounds with unknown mechanisms of action from natural products libraries. Application to natural product extracts identified hits from a range of taxonomic groups. Screening of synthetic compounds and natural products should identify novel AP-1 inhibitors that may be useful in the prevention and treatment of cancers. (Journal of Biomolecular Screening 2007:133-139) 
INTRODUCTION
C ARCINOGENESIS IS A MULTISTAGE PROCESS that can be described by 3 distinct steps: initiation, promotion, and progression. Transcription factor activator protein-1 (AP-1) transactivation is required for tumor promotion and progression, the rate-limiting steps in this multistage process. 1 AP-1 exists as a heterodimer of Jun (c-Jun, Jun B, and Jun D) and Fos (c-Fos, Fos B, Fra 1, and Fra 2) proteins or as a homodimer of Jun proteins. 2 Blocking AP-1 activity by a dominant negative c-Jun mutant, TAM67, has been shown to inhibit phorbol ester-induced transformation and tumorigenesis without inhibiting cell proliferation or cell survival. 3, 4 Molecules that mimic TAM67 in inhibiting 12-O-tetradecanoyl phorbol-13-ester (TPA)-stimulated AP-1 activity may be valuable for the prevention and treatment of cancers.
Here we describe the development, optimization, validation, and preliminary screening results for a cell-based highthroughput screening (HTS) protocol to identify inhibitors of AP-1. The assay uses fluorescence resonance energy transfer (FRET) technology to quantify expression of a β-lactamase reporter driven by a promoter bearing 3 AP-1 binding sites (TGAGTCA). 5 By pairing this AP-1 reporter assay with an XTT assay to evaluate cell viability, cytotoxic compounds can be eliminated. Because any noncytotoxic compounds that inhibit AP-1 activity may be general transcriptional or translational inhibitors, compounds found to significantly affect hypoxia-induced factor 2α (HIF-2 α) activity in a separate assay 6 were also eliminated. This reproducible and robust highthroughput screen was able to identify known AP-1 modulators from synthetic compound and natural product libraries. Further analysis of the results should yield novel and chemically diverse specific AP-1 inhibitors.
MATERIALS AND METHODS

Materials
The CellSensor AP-1-bla HEK293T cells, which stably express a plasmid containing β-lactamase under the control of an AP-1 promoter, and the LiveBLAzer FRET B/G Loading Kit were obtained from Invitrogen Drug Discovery Solutions (Madison, WI). Curcumin, nordihydroguaiaretic acid (NDGA), and staurosporine were obtained from Sigma (St. Louis, MO). TPA was obtained from Alexis Biochemicals (Lausen, Switzerland). All cell culture components were from Invitrogen (Carlsbad, CA). Black-wall, clear-bottom 384-well polylysine-coated assay plates were obtained from Corning (Corning, NY). 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide (XTT) and natural products were obtained from the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (Frederick, MD). Natural product extracts were obtained from the Natural Products Support Group of the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (Frederick, MD). A library of protein kinase modulators was obtained from BioMol (Plymouth Meeting, PA).
Cell culture conditions
CellSensor AP-1-bla HEK293T cells (Invitrogen) were maintained in Dulbecco's modified eagle's medium (DMEM) supplemented with 10% heat-inactivated dialyzed fetal bovine serum (FBS), penicillin-streptomycin (100 IU/mL and 100 µg/mL, respectively), nonessential amino acids (0.1 mM), HEPES (25 mM), sodium pyruvate (1 mM), and blasticidin (5 µg/mL). Cells at approximately 70% confluency were trypsinized, resuspended in medium containing no blasticidin, and seeded in 384-well assay plates (40 µL per well) using a µFill microplate liquid dispenser (BioTek, Winooski, VT). The cells were then allowed to attach (37 °C, incubator) for ≥ 18 h.
β β-lactamase assay
Staurosporine inhibits AP-1 activity by blocking various protein kinases and was used as the control inhibitor compound for screening. Staurosporine was diluted to 10 × final concentration in Ca 2+ /Mg 2+ -free phosphate-buffered saline (PBS; BioWhittaker, Walkersville, MD). The final concentration of staurosporine was 0.2 µM. Staurosporine, DMSO control, and test compounds (5 µL per well) were first added to the cells using a Biomek FX (Beckman Coulter, Fullerton, CA). Curcumin, a natural product inhibitor of AP-1, was used for assay optimization. The final DMSO concentration ranged from 0.1% to 1% (v/v) and had no effect on cell growth or on the β-lactamase assay (data not shown). Cells were incubated at 37 °C for 1 h and then treated with TPA (5 µL of 10× solution was added per well for a final concentration of 10 µg/mL) to induce AP-1 activity. Cells were incubated at 37 °C for 18 h. For quantitation of β-lactamase activity, LiveBLAzer FRET substrate was added (5 µL of 10 × solution per well), and cells were incubated and light protected at room temperature for 2 h. Fluorescence was read on a Tecan Safire fluorescent plate reader in bottom read mode (409 nm excitation, 460 nm emission followed by 409 nm excitation, 530 nm emission). The background, defined as the fluorescence of the substrate with no cells present, was subtracted from each reading, and then the ratio of the emission at 460 nm to the emission at 530 nm was calculated. This ratio directly correlates to β-lactamase activity (i.e., an increase in the ratio reflects increased activity and vice versa). 5
Cytotoxicity assay
The compounds were also tested for cytotoxicity. Immediately after screening for AP-1 activity, the plates were washed (3× 100 µL per well) with PBS containing Ca 2+ and Mg 2+ (Quality Biological, Gaithersburg, MD) to eliminate absorbance by the substrate buffer. Cell number and viability were assessed by XTT assay. 7
Data analysis
Z´ values were calculated using methods described by Zhang et al. 8 Background was defined as the fluorescence of the substrate in cell-free wells. Positive (0.2 µM staurosporine) and negative (TPA only) controls (8 wells each) were included in each screening plate. The ratio of each background-subtracted reading was obtained for each well, and the AP-1 activity of each sample was normalized to the TPA-stimulated response: (RFU 460 nm / RFU 530 nm ) test compound /(RFU 460 nm /RFU 530 nm ) ave 10 ng/mL TPA × 100%. Compounds identified as hits reduced AP-1 activity to less than 50% of TPA-stimulated control activity. The cytotoxicity of test compounds was determined via XTT assay, and cytotoxicity was defined as inhibition of absorbance by more than 50%. Noncytotoxic inhibitors of TPA-stimulated AP-1 activity that also inhibited HIF-2α activity were not included as "hits." These compounds were identified as nonspecific transcription or translation inhibitors. AP-1 hits that were not cytotoxic and did not affect HIF-2α activity were reassayed in quadruplicate, and the results were analyzed by calculating confidence intervals. 9 A "confirmed hit" was defined as a compound in which reassay showed ≤ 50% of TPA-stimulated AP-1 activity at a 95% confidence interval. The IC 50 values were calculated using SigmaPlot (SPSS, Inc., Chicago, IL) 4-parameter logistic nonlinear regression analysis.
Although false-positive and false-negative rates were not analyzed rigorously, reassay/hit confirmation results were used for estimates. These are based on the assumption that the average (n = 4 or 5) of the original screening run and multiple repeat assays approximates the "true" activity for a given sample. Primary hits for which the overall average was > 50% of control give an estimate of the number of false positives under screening conditions. False-negative reads were defined as wells in reassay plates where the average for the sample was < 50% of control, but the individual well value was > 50%.
RESULTS
Assay optimization
The assay was optimized to maximize inhibition of TPA-stimulated AP-1 activity using control compounds curcumin and staurosporine. Assay conditions were varied systematically, and the following optimal parameters were determined: After defining the optimal conditions, the parameters were varied to determine the range of acceptable assay conditions. The results (fluorescence ratio) varied from optimal conditions by 19% when cells were plated from 8500 to 25,500 cells per well. There was a 28% variation when substrate concentration was decreased or increased by 2-fold. There was a 13% variation for substrate loading time of 1 to 4 h, so 2 h was chosen as optimal. The most important factor for assay performance was TPA concentration: when there was a 2-fold decrease in TPA concentration, there was a 48% variation from results obtained under optimal conditions, but when the TPA concentration was increased by 2-fold, the results varied by only 6%.
Assay reproducibility
To evaluate the reproducibility of the screening assay, four 384-well plates containing 1408 compounds total were chosen at random from a synthetic library obtained from ChemBridge (San Diego, CA). The compounds were assayed at 10 µM (final concentration) under optimal conditions independently on 2 days in triplicate. Figure 2 shows the ratio of the 2 fluorescent reads for 2 assay runs. The slope of the curve was 1.03, and the correlation coefficient was 0.91. For ChemBridge plates screened over 13 days, the average Z´ was 0.74 ± 0.11 (n = 272).
Application of assay to known compounds
Before screening began, the assay was applied to compounds known to inhibit AP-1 and to a set of protein kinase inhibitors. Figure 3A shows representative dose-response curves for 2 known AP-1 inhibitors, curcumin and nordihydroguaiaretic acid. 10 Figure 3B shows the activity of various inhibitors of kinases upstream of AP-1: protein kinase C (PKC) 11 protein kinase) kinase (MEK1/2). 12 PKC inhibitors staurosporine, 13 calphostin C, 14 bisindolylmaleimide (BIM) III, 15 and Go6983 16 and the MEK1/2 inhibitor U0126 17 reduced TPA-stimulated AP-1 activity to less than 50% of TPA-only control. BIM V, an inactive bisindolylmaleimide analog, 15 had no effect. The IC 50 values for TPA-stimulated AP-1 activity were calculated: staurosporine, 0.2 µM; calphostin C, 8 µM; BIM III, 1.1 µM; Go6983, 0.1 µM; and U0126, 0.2 µM.
Effects of natural product extracts on assay performance
To evaluate the effects of natural product extracts on the assay performance, eight 384-well plates containing 2816 samples were chosen from the National Cancer Institute (NCI) Natural Product Extract Library and assayed at 10 µg/mL. The chosen plates contained both organic and aqueous extracts from fungal, algal, marine, and plant sources. To determine the effects of extracts on substrate uptake and cleavage, all the samples were added immediately before substrate loading. TPA-stimulated AP-1 activity was not affected by the extracts (95.8% ± 8.2% of control). No autofluorescence was observed at the standard assay wavelengths. To determine the effect of the extracts on AP-1 inhibition by a known inhibitor, the samples were assayed in the presence of staurosporine. AP-1 activity in the presence of staurosporine and extracts was 21.9% ± 8.1% of control (TPA stimulated) compared to 25.5% ± 2.6% for staurosporine without extracts.
Validation by screening of synthetic, pure natural product, and natural product extract libraries
More than 120,000 synthetic compounds, 4500 purified natural products, and 138,000 natural product extracts from various libraries were screened using the AP-1 β-lactamase assay followed by evaluation of cytotoxicity. Figure 4 shows reassay data for confirmed hits from a small kinase inhibitor library. The U0126, 17 staurosporine, 13 Ro31-8220 (PKC inhibitor), 18 GF109203 (PKC inhibitor), 15 and AG1478 (epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor) 19, 20 all blocked TPA-stimulated activity by more than 50% with a 95% confidence level. Table 1 includes activities of several confirmed hits from the kinase inhibitor library and libraries of pure natural products. Except for NDGA and curcumin, which were used in assay development and validation, all of the compounds listed in Table 1 were identified by library screening. Table 2 summarizes results of an investigation of false-positive and false-negative rates for the screening assay. The ChemBridge synthetic compound library is not included in this analysis because it was used primarily for assay development and validation. Primary hit rate ranged from ~0.8% for natural product extracts up to nearly 2% for pure compounds. Synthetic and pure natural products are combined in Table 2 because results were similar for these 2 classes of compounds.
Estimation of false-positive and false-negative rates
DISCUSSION
A FRET-based, AP-1 β-lactamase reporter was used to develop an HTS assay to identify inhibitors of the oncogenic transcription factor AP-1. The assay is robust for TPA induction and substrate loading times, so variations in timing have minimal effects on the results. The critical factor for assay performance is TPA concentration. When TPA concentration was halved, the results varied by nearly half as well. However, the results are not affected by addition of too much TPA, indicating that a threshold of AP-1 induction must be reached to ensure proper results. Reproducibility was demonstrated by repeated testing of the same samples (Fig. 2) , indicating that there is a low probability of generating false-positive or false-negative results. Z´ was consistently high, with an average of 0.69 ± 0.13 over 742 plates screened over the course of the campaign.
The major advantage of using this FRET-based β-lactamase assay over other reporter systems, such as luciferase, is the ratiometric readout. The fluorescence ratio gives a quantitative AP-1 response that is normalized to reduce error due to experimental noise. The ratiometric readout also reduces problems associated with autofluorescence, which are common in nonratiometric fluorescence-based assays of natural products. There still remains the possibility of test compounds quenching fluorescence at the assay wavelengths, but as the results show, this is not an apparent problem.
To ensure that natural product extracts, which can often be autofluorescent, would not alter assay performance, aqueous and organic samples of various origins were tested to evaluate their effects on substrate processing and fluorescent signal. The 2816 randomly chosen fungal, algal, marine, and plant extracts showed no autofluorescence at the assay emission wavelengths, and they had no effect on substrate processing. Similarly, the extracts had no effect on AP-1 inhibition by a control inhibitor.
A "hit" was defined as a compound that inhibited TPAstimulated AP-1 activity by more than 50%. Because cytotoxic compounds could be scored as AP-1 inhibitors using this technique, the AP-1 assay was coupled with an XTT assay to determine cell viability to reduce false positives. Compounds that reduced viable cell numbers by more than 50% were considered cytotoxic. Before reassay to confirm activity, noncytotoxic primary AP-1 hits were compared to the results of a HIF-2α inhibitor screen 6 to eliminate any nonspecific inhibitors of transcription or translation.
Before screening, the assay was applied to known AP-1 and protein kinase inhibitors. Curcumin and NDGA, known AP-1 inhibitors, 10 performed as expected in the β-lactamase assay. The dose-response curve for curcumin shows inhibition of AP-1 comparable to the IC 50 values reported for its activity on c-Jun N-terminal kinase (JNK) and ERK, 2 kinases upstream of AP-1 (Fig. 3A) . 21 Screening of protein kinase inhibitors identified several PKC and MEK1/2 antagonists as AP-1 inhibitors, whereas inactive analogs showed no effect on AP-1 activity (Fig. 3B) .
False-positive and, even more, false-negative rates are notoriously difficult to assess in screening campaigns. An attempt was made to use reassay data to provide estimates (see Table 2 ). All groups of samples tested (synthetic, pure natural products, and natural product extracts) had similar false-positive rates (~1%) calculated from hits subsequently shown to be inactive. Although the assay incorporated filters where possible to eliminate false positives due to cytotoxicity or nonspecific effects on transcription or translation, 50% of pure compound hits did not show activity upon reassay. Strikingly, this value was as low as 10% to 15% for natural product extracts, indicating that these had a far lower proportion of true actives. This could be due, in part, to the complex nature of these mixtures. Most of the hits that failed upon reassay were "borderline" (i.e., < 1 standard deviation from the 50% hit cutoff [data not shown]).
The overall apparent false-negative rate suggests that a significant number of active compounds and extracts may be missed in this assay. This observation, along with the possible masking of activity by cytotoxic components in extracts (up to 10% of extracts were cytotoxic-data not shown), leads to the conclusion that additional screening with alternative approaches may be fruitful. An alternative approach would be to prefractionate extracts to remove cytotoxic components before assaying. Nevertheless, noncytotoxic, specific AP-1 inhibitors were identified from libraries of synthetic compounds (28 confirmed actives), pure natural products (58), and natural product extracts (48). Phorbol ester-stimulated AP-1 activation can be inhibited by multiple mechanisms, including phorbol ester antagonism, 22 aberrant PKC localization, 23 inhibition of PKC activity, 24 inhibition of other protein kinases, 25 or the disruption of AP-1 signaling complex and DNA binding. 10 This assay was able to detect compounds apparently working through each of these mechanisms ( Fig. 4 and Table 1 ). Bryostatins are known ligands of PKC that can act to inhibit its phorbol ester-induced activity. 26, 27 Geldanamycins are heat shock protein 90 inhibitors that can inhibit phorbol ester-induced AP-1 activity by inhibiting c-Jun expression and JNK activation. 28 Reserpines and nigericins both affect PKC localization, which can lead to aberrant signaling and reduced AP-1 activation. 29, 30 As noted above, the natural products curcumin and NDGA were used as controls. All of the other compounds listed in Table 1 were identified from libraries in the screening campaign. In addition to detection of known compounds with known mechanisms of action, a large number of unclassified compounds were also identified from libraries provided by the Developmental Therapeutics Program at NCI. For many of these, interesting biological activities have been reported, including possible antitumor activities. Further investigation will focus on characterizing these activities and their relationships to inhibition of AP-1. Finally, the identification of natural product extracts from a variety of taxonomic groups, including marine, plant, and fungal organisms, is expected to lead to the purification and characterization of novel natural products that will affect AP-1 signaling. As far as we are aware, this is the first systematic, high-throughput investigation of natural product extracts for modulation of AP-1 activity.
High-Throughput
Further testing will be done to identify which, if any, of the active compounds from this screen act on kinases upstream of AP-1. Additional analysis will focus on effects of the compounds on nuclear factor kappa B (NF-κB), another oncogenic transcription factor inhibited by the dominant negative c-Jun TAM67 when it specifically inhibits transformation and tumorigenesis. 31 Because AP-1 transactivation, which plays an integral part in tumor promotion and progression, can be blocked without adverse effects, inhibitors identified by this screen could prove invaluable for cancer prevention and treatment. a. For primary "hits" active upon reassay (i.e., average of original activity and reassay activity was < 50% of control), individual wells were assessed. Those that showed > 50% of control activity were considered to be false-negative wells. b. Primary "hits" (samples giving < 50% of control activity at 10 µM in the primary screening assay) were reassayed, typically in quadruplicate, at 10 µM. Inactive primary hits are those for which the average of the activity in the initial screen and reassay activity was > 50% of control.
